Silence Therapeutics plc — Director's Dealing 2025

Jan 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silence Therapeutics plc (SLN)
CIK: 0001479615
Period of Report: 2025-01-02

Reporting Person: Ede-Golightly James (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-02	Share Option (Right to Buy)	$2.40	A	48000	Acquired	2035-01-02	Ordinary Shares (48000)	Direct

Footnotes

F1: This option shall vest in equal monthly installments over a three-year period measured from one month following January 2, 2025, subject to the Reporting Person's continuous service as of each applicable vesting date.